The special nature of pharmaceutical IP
Drugs are among the most IP-intensive products. An innovative drug's portfolio typically spans compound patents (the core), crystal-form, formulation, use (indication) and process patents, plus data exclusivity — a multi-layered protection system.
China's Measures for the Early Resolution of Drug Patent Disputes (2021) — its version of "patent linkage" — moved China into a new era by embedding patent review into the generic-registration process and resolving disputes before launch, replacing the old "launch first, litigate later" model.
China's drug patent linkage system
Framework
- Patent Law (2020), Art. 76 — early-resolution clause
- Measures for Early Resolution of Drug Patent Disputes (NMPA & CNIPA, 2021)
- SPC judicial interpretation on patent disputes for drugs under registration (2021)
The patent information registration platform ("Orange Book")
Originators must register relevant patents on the platform within 30 days of receiving a drug registration certificate — the starting point of the entire system.
- Registrable: compound, composition and medical-use (indication) patents.
- Not registrable: intermediates, metabolites and crystal-form patents (the latter contested in practice).
- Consequences: wrongful registration may be challenged; omitted patents are not covered by linkage (though ordinary infringement actions remain).
The four patent declarations (P1–P4)
| Declaration | Meaning | Effect |
|---|---|---|
| P1 | No relevant patent is listed on the platform. | No patent obstacle; ANDA proceeds. |
| P2 | The listed patent has expired or is invalid. | No patent obstacle. |
| P3 | The patent is valid; the applicant will not market before expiry. | Approval noted "not marketable before patent expiry". |
| P4 | The patent should be invalidated, or the generic does not infringe. | Triggers the patent-challenge procedure. |
The P4 challenge — the 45-day window
After a P4 declaration, the generic must notify the originator's MAH within 10 working days. The originator then has 45 days to sue at the Beijing IP Court or seek an administrative ruling from CNIPA.
- If the originator sues within 45 days: CDE suspends technical review for up to 9 months, pending the court/CNIPA decision.
- If not: CDE continues review, unaffected by the patent.
The 12-month first-generic exclusivity: the first generic to successfully challenge the originator's patent (a P4 declaration upheld — patent invalidated or non-infringement found) and win ANDA approval obtains a 12-month market exclusivity, during which CDE will not approve other same-product generics. This is the highest reward in the patent war, and the system's most attractive design.
The Bolar exemption — generics' shield
The Bolar exemption (Patent Law Art. 75(5)) permits manufacturing, using or importing a patented drug or device during the patent term for the purpose of providing information needed for regulatory approval, without constituting infringement.
- Function: allows generics to run BE studies before patent expiry so they can launch promptly at expiry.
- Scope: strictly limited to acts "necessary to provide regulatory information" — beyond that, manufacture and sale still infringe.
- Grey area: whether it covers activities for foreign regulators (FDA, EMA) remains unsettled in Chinese practice.
Data exclusivity
Data exclusivity is an IP right independent of patents. Innovator and improved-new-drug clinical trial data receive a protection period during which generics may not rely on the originator's data ("free-riding"). The two protections stack: if a patent expires before data exclusivity, the generic must still wait out the data-protection term — and vice versa.
TCM variety protection
China-specific protection independent of patents: a certified "protected TCM variety" cannot be produced by others during its protection period.
- Grade 1: 30, 20 or 10 years.
- Grade 2: 7 years.
- Relationship to patents: the two run in parallel; companies should use both in an integrated strategy.
Trade secrets — the invisible shield
Not all technical information suits patent disclosure. Process details, QC methods and know-how are better protected as trade secrets — unlimited in time, but requiring a strict confidentiality system.
- Reasonable measures: encryption, access controls, confidentiality agreements and de-confidentialisation periods for departing staff.
- Non-compete and confidentiality: careful drafting of these clauses decides whether a company can protect its secrets amid staff turnover.
How we help
- Originator patent strategy: comprehensive China filings and registration across compound, crystal-form, formulation, use and process.
- Generic challenge strategy: P1–P4 analysis, FTO searches, invalidity assessment and P4 litigation.
- Orange Book registration and maintenance: correct registration and defence against challenges.
- IP due diligence in deals: patent-asset review and FTO analysis for license-in/out.
- Trade-secret program: designing protection covering technology, personnel and contracts.